引正基因 is a platform technology solutions provider focused on foundational gene‑editing tool development. The company develops next‑generation CRISPR‑based gene‑editing tools designed to improve editing efficiency and precision while reducing off‑target effects. It positions itself as a technology company building underlying capabilities for gene editing. The article reports the company completed a Pre‑A+ financing round of tens of millions of US dollars. Investors in the round include 晟德医药集团 and its 顺天医药, along with 启明创投, the Hong Kong SAR Innovation & Technology Venture Fund, and the Hong Kong Science Park Venture Fund. No operating metrics (revenue/users) or founding year are disclosed in the article.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2024